

NEWS

December 28, 2011
Gene Techno Science Co., Ltd.
President
Kawaminami Masanari

The first application for a Biosimilar (rhG-CSF) in Japan

The first regulatory application in Japan for a biosimilar of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was submitted at December 26, 2011 by Fuji Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd.

The development of this product was announced in February 2010 between Gene Techno Science Co., Ltd and Fuji Pharma Co., Ltd., and the clinical trial was proceeded under the collaboration agreement of clinical development of the rhG-CSF between Mochida Pharmaceutical Co., Ltd and Fuji Pharma Co., Ltd.

Recombinant human G-CSF, synthesized using biological cells, is widely accepted and distributed for a chemotherapy drug of neutropenia. They also plan a co-promotion of the product for rapid and effective market penetration.